Gilead yanks out a thorn in its side in major court ruling
The U.S. Court of Appeals for the Fourth Circuit upheld a preliminary injunction in favor of Gilead Sciences (GILD), blocking alternative funding programs from importing cheaper foreign versions of its HIV drug Biktarvy and selling them to U.S. patients, according to CNBC and Bloomberg Law. Gilead said Biktarvy generated about $14.3B in 2025 sales and it raised 2026 guidance to $29.8B-$30.1B.
How this was made
The 30-second read
Why it matters
By affirming that the foreign and U.S. products differ in meaningful quality-control terms, the court blocks named AFP-linked distribution paths, supporting U.S. pricing assumptions used in guidance.
Market read
A court decision directly supports the pricing model for Gilead’s core HIV franchise and removes a legal risk, while investors still need pipeline execution.
What to watch
The article does not quantify how much AFP volume was at stake; the market may discount the ruling’s incremental revenue impact versus broader pipeline catalysts.
Background
Gilead sued after a Maryland patient received Biktarvy from Turkey via an alternative funding program, arguing the imported product was not materially the same as the U.S. version.
Ticker impact
Fourth Circuit upheld a preliminary injunction blocking alternative funding programs from importing cheaper foreign Biktarvy versions into the U.S.
Bullish bias for GILD as the decision supports the company’s assumption of continued domestic Biktarvy pricing.
The article ties the injunction to U.S. pricing mechanics and notes management raised full-year sales and HIV growth guidance, explicitly assuming domestic prices hold.
Market effects
Reinforces IP and supply-chain enforcement risk for the alternative funding program model in HIV drugs, potentially limiting discount import arbitrage.
U.S. healthcare pricing and reimbursement channels face tighter constraints for AFP-driven importation.
Highlights cross-border drug pricing differentials and how U.S. courts may limit parallel import strategies.
Counterpoint
Even with the injunction, Gilead’s stock upside still depends on execution of upcoming FDA decisions and competitive dynamics in HIV.
Key entities
- companyGilead Sciences
Defendant and beneficiary of the Fourth Circuit ruling protecting U.S. Biktarvy pricing.
- drugBiktarvy
Gilead’s top HIV medicine at the center of the import injunction.
- alternative funding programRx Valet
AFP named in the lawsuit that facilitated cheaper foreign sourcing.
- insurer/plan administratorMeritain Health (Aetna unit)
Named party tied to employer health plan purchasing routes.
- pharmacy benefit managerPro-Act
Named party in the lawsuit connected to the distribution structure.
